論文 - 宇原　久

寒冷蕁麻疹の2例

大橋 隆宏, 澄川 靖之, 高橋 宏征, 米田 大介, 山口 華央, 加瀬 貴美, 菅 裕司, 宇原 久

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  128 ( 4 ) 607 - 607  2018年04月

Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan

Hisashi Uhara

International Journal of Clinical Oncology ( Springer Tokyo )  1437-7772 (Electronic)   1 - 7  2018年02月  [査読有り]

　概要を見る

New therapeutic strategies including immunotherapy and selective molecular target inhibitors have brought about a new era in the treatment of patients with advanced melanoma. In Japan, the immune checkpoint inhibitors ipilimumab, nivolumab and pembrolizumab, the BRAF inhibitor (BRAFi) vemurafenib, dabrafenib and MEK inhibitor (MEKi) trametinib have been available for the treatment of unresectable and metastatic melanoma. The BRAFi + MEKi combination shows high response rates (60–70%) and rapid response induction associated with symptom control, with a progression-free survival of 12 months. Nivolumab and pembrolizumab offer moderate response rates (30–40%) and long survival (3- to 5-year survival: 30–50%). In Japan, treatment options for the first-line setting frequently include nivolumab or pembrolizumab monotherapy and BRAFi + MEKi combinations (for patients with BRAF-mutant melanoma). Ipilimumab is included in the second-line setting, and the nivolumab + ipilimumab combination has not been approved yet in Japan. Although these medications have demonstrated impressive efficacy, the clinical trials and real-world data have shown that the clinical benefit is not fully satisfactory. We have to carefully manage a new class of adverse events due to these medicines. Moreover, biomarkers are emerging with which we can identify a population that would experience more benefits without severe adverse events.

DOI

巨大な褐色斑と多発性色素性母斑を伴ったびまん性神経線維腫

肥田 時征, 杉田 真太朗, 菅原 太郎, 山下 利春, 宇原 久

日本レックリングハウゼン病学会学術大会プログラム・抄録集 ( 日本レックリングハウゼン病学会 )  9回   30 - 30  2018年02月

Imiquimod 5% cream as a therapeutic option for extramammary Paget's disease.

Masahide Sawada, Junji Kato, Toshiharu Yamashita, Akihiro Yoneta, Tokimasa Hida, Kohei Horimoto, Sayuri Sato, Hisashi Uhara

The Journal of dermatology   45 ( 2 ) 216 - 219  2018年02月  [査読有り]  [国際誌]

　概要を見る

A wide local excision is the standard treatment for extramammary Paget's disease (EMPD), though this treatment often leads to permanent anogenital mutilation and functional impairment. The purpose of our study is to evaluate the efficacy and safety of the topical application of imiquimod 5% cream for non-invasive EMPD. We examined nine patients with EMPD. Eight of the nine patients were treated with imiquimod 5% cream three times per week for 16 weeks; one case was treated for 6 weeks. The response rate was 100% including five complete remissions. Local irritation was observed in three patients, which was controlled by a provisional withdrawal of the treatment. These results suggest that imiquimod 5% cream may be considered an alternative therapeutic option for the treatment of non-invasive EMPD.

DOI PubMed

肺扁平上皮癌を合併したBazex症候群の1例

塩野谷 愛香, 肥田 時征, 宇原 久, 西坂 尚大, 汐谷 心

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  128 ( 1 ) 63 - 63  2018年01月

乳房Paget病のダーモスコピー所見の検討

江畑 加奈子, 肥田 時征, 澄川 靖之, 宇原 久, 久冨 五郎, 前田 和男, 疋田 政博, 松本 光博

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  128 ( 1 ) 59 - 59  2018年01月

悪性黒色腫患者における好中球・リンパ球比の有用性

松井 馨之, 加藤 潤史, 箕輪 智幸, 澤田 匡秀, 佐藤 さゆり, 堀本 浩平, 肥田 時征, 宇原 久

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  128 ( 1 ) 62 - 62  2018年01月

Successful TS-1 monotherapy as the second-line treatment for advanced extramammary Paget's disease: A report of two cases.

Junji Kato, Tokimasa Hida, Toshiharu Yamashita, Shiori Kamiya, Kohei Horimoto, Sayuri Sato, Hitomi Takahashi, Masahide Sawada, Mao Yamada, Hisashi Uhara

The Journal of dermatology   45 ( 1 ) 80 - 82  2018年01月  [査読有り]  [国際誌]

　概要を見る

There is no standard chemotherapeutic treatment for advanced extramammary Paget's disease, though the effectiveness of some chemotherapy regimens, including docetaxel, has been reported. In this report, we report that TS-1 monotherapy was effective in two patients with advanced extramammary Paget's disease after docetaxel treatment failure. TS-1 monotherapy may be useful as the second-line treatment for patients with advanced extramammary Paget's disease.

DOI PubMed

局所麻酔薬による即時型アレルギーが疑われた38例についての検討

江畑 加奈子, 澄川 靖之, 肥田 時征, 神谷 崇文, 石井 泰江, 菅 裕司, 加藤 潤史, 堀本 浩平, 宇原 久

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  128 ( 1 ) 62 - 62  2018年01月

Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan

Uhara, H. Kiyohara, Y. Tsuda, A. Takata, M. Yamazaki, N

Clin Transl Oncol   20 ( 2 ) 169 - 175  2018年  [査読有り]

Nevus cells of cardiofaciocutaneous syndrome bear BRAF germ-line and somatic double mutations

Hida, T. Sato, S. Okura, M. Uhara, H

Eur J Dermatol   1952-4013 (Electronic)  2018年  [査読有り]

Multiple Melanonychia Striata as a Sign of Connective Tissue Disorders

Edamitsu, T. Uhara, H. Minagawa, A. Okuyama, R

J Am Acad Dermatol   1097-6787 (Electronic)  2018年  [査読有り]

Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma

Sato, M. Uhara, H. Koga, H. Okuyama, R

J Dermatol   45 ( 10 ) 287 - 289  2018年  [査読有り]

Xeroderma pigmentosum group D: Report of a novel combination of ERCC2 variations and its phenotype

Hida, T. Okura, M. Kobayashi, K. Yamashita, T. Nishigori, C. Uhara, H

J Dermatol   1346-8138 (Electronic)  2018年  [査読有り]

Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma

Kamiya, S. Kato, J. Kamiya, T. Yamashita, T. Sumikawa, Y. Hida, T. Horimoto, K. Sato, S. Takahashi, H. Sawada, M. Kubo, T. Torigoe, T. Uhara, H

Asia Pac J Clin Oncol   1743-7563 (Electronic)  2018年  [査読有り]

Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients

Omodaka, T. Minagawa, A. Uhara, H. Wakamatsu, K. Koizumi, T. Yokokawa, Y. Koga, H. Okuyama, R

J Dermatol   1346-8138 (Electronic)  2018年  [査読有り]

Successful rechallenge with nivolumab therapy after radiotherapy in mucosal melanoma

Kato, J. Hida, T. Horimoto, K. Sato, S. Kobayashi, K. Sawada, M. Fujioka, M. Tsuchiya, T. Someya, M. Uhara, H

J Dermatol   1346-8138 (Electronic)  2018年  [査読有り]

Rechallenge With Nivolumab After Vemurafenib Treatment of Initially Nivolumab-Resistant Advanced Melanoma

Kato, J. Hida, T. Kamiya, T. Sato, S. Takahashi, H. Torigoe, T. Uhara, H

JAMA Dermatol   154 ( 5 ) 621 - 622  2018年  [査読有り]

Cytokeratin 19 expression is a risk factor for metastasis in cutaneous squamous cell carcinoma

Kato, J. Hida, T. Sugita, S. Hasegawa, T. Kamiya, S. Horimoto, K. Sato, S. Sawada, M. Uhara, H

J Eur Acad Dermatol Venereol   32 ( 7 ) 299 - 301  2018年  [査読有り]

Granulocyte colony-stimulating factor-producing melanoma treated with the combination of dabrafenib and trametinib

Minowa, T. Kato, J. Hida, T. Horimoto, K. Sato, S. Sawada, M. Takahashi, H. Uhara, H

Int J Dermatol   57 ( 7 ) 31 - 33  2018年  [査読有り]